Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2014

View Archived Issues

Eisai begins phase III trial of eribulin mesilate in metastatic breast cancer

Epizyme achieves lead candidate selection milestone in GSK collaboration

Phase III femoral nerve block study of Exparel meets primary endpoint

Teva presents phase II results for laquinimod in Crohn's disease

Human recombinant peptide sponge developed as ischemic stroke cell therapy scaffold

Alnylam Pharmaceuticals closes alliance with Genzyme

Aires Pharmaceuticals is now a subsidiary of Mast Therapeutics

Protective mechanisms for cancer brain metastases identified

Cadazolid receives FDA QIDP designation for Clostridium difficile-associated diarrhea

Galapagos provides update on GSK-2586184 in psoriasis, lupus and ulcerative colitis

Merck & Co. patents novel ROR-gamma inhibitors

Biotie decides to develop SYN-120 internally, gives update on Neurelis acquisition

Celsion reports interim data from phase II DIGNITY trial in breast cancer

Pernix Therapeutics signs agreement with Osmotica Pharmaceutical to promote Khedezla

Canadian researchers prepare new vaccines for chlamydial infection

Intraparenchymal transplantation of SB-623 leads to neurological improvements in phase I/II trials

Scientists at Merck KGaA disclose novel PARP-1/TANK inhibitors

New fusion proteins designed for cancer and autoimmune diseases

European CHMP recommends approval of tablet formulation of Noxafil

Roche patents new immunocytokines for inflammatory diseases

Roche and Discuva collaborate on antibiotics against multidrug-resistant bacteria

Promacta submitted to FDA for severe aplastic anemia

Bayer Yakuhin seeks Japanese approval of Eylea for diabetic macular edema

Cell Therapeutics initiates PERSIST-2 trial of pacritinib in myelofibrosis

Endo and Paladin Labs combine to form Endo International

Data monitoring committee recommends termination of METLung study of onartuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...